With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.1662-01-7,4,7-Diphenyl-1,10-phenanthroline,as a common compound, the synthetic route is as follows.
General procedure: The copper-phosphine complex (1.00 mmol) together with 10.0 ml of CHCl3 is placed in a Schlenk vessel. The phosphine (1.00 mmol) is added to this solution until it is completely dissolved. A solution of the N-ligand (1.00 mmol) in 2 ml of CHCl3 is then added over a period of 30 minutes. The mixture is subsequently stirred at room temperature for a further 30 minutes. After removal of the CHCl3 in vacuo, the resulting solid is recrystallized from CH2Cl2 and Et2O.Example 50 (4,7-diphenyl-1,10-phenanthroline)bis(triphenylphosphine)copper(I) nitrate (4,7-Diphenyl-1,10-phenanthroline)bis(triphenylphosphine)copper(I) nitrate was prepared from bis(triphenylphosphine)copper(I) nitrate (650 mg, 1.00 mmol), 4,7-diphenyl-1,10-phenanthroline (339 mg, 1.00 mmol) and triphenylphosphine (262 mg, 1.00 mmol). This gives (4,7-diphenyl-1,10-phenanthroline)bis(triphenylphosphine)copper(I) nitrate (980 mg, 99%) as a yellow solid. 31P NMR (162 MHz, CDCl3) delta=3.32 (s, 1P) ppm. Anal. calc. for C48H36Cl2CuN3O3P2: C, 59.8, H, 3.9, N, 4.3. Found: C, 59.0, H, 3.8, N, 4.6.
The synthetic route of 1662-01-7 has been constantly updated, and we look forward to future research findings.
Reference£º
Patent; BASF SE; Goossen, Lukas J; Rodriguez Garrido, Nuria; Manjolinho Costa, Filipe; Lange, Paul P.; US2014/12000; (2014); A1;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI